CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2567 views | HTML 2520 views | ?
Hinrich P. Hansen1, Ahmad Trad2, Maria Dams1, Paola Zigrino3, Marcia Moss4, Maximilian Tator1, Gisela Schön1, Patricia C Grenzi1, Daniel Bachurski1, Bruno Aquino5, Horst Dürkop6, Katrin S Reiners1, Michael von Bergwelt-Baildon1, Michael Hallek1, Joachim Grötzinger2, Andreas Engert1, Adriana F Paes Leme5, Elke Pogge von Strandmann1
1Department of Internal Medicine I, University of Cologne, Cologne, Germany
2Department of Biochemistry, University Kiel, Kiel, Germany
3Department of Dermatology, University of Cologne, Cologne, Germany
4BioZyme Inc., Apex, North Carolina, USA
5Brazilian Biosciences National Laboratory, LNBio, CNPEM, Campinas, Brazil
6Pathodiagnostik Berlin, Berlin, Germany
Hinrich P. Hansen, e-mail: [email protected]
Keywords: Hodgkin lymphoma, extracellular vesicle, CD30, ADAM10, Brentuximab-Vedotin
Received: January 11, 2016 Accepted: March 31, 2016 Published: April 20, 2016
The goal of targeted immunotherapy in cancer is to damage both malignant and tumor-supporting cells of the microenvironment but spare unaffected tissue. The malignant cells in classical Hodgkin lymphoma (cHL) selectively express CD30. They release this receptor on extracellular vesicles (EVs) for the tumor-supporting communication with CD30 ligand (CD30L)-positive bystander cells. Here, we investigated how CD30-positive EVs influence the efficacy of the CD30 antibody drug conjugate (ADC) Brentuximab Vedotin (SGN-35). The malignant cells and the EVs expressed the active sheddase ADAM10. ADAM10 cleaved and released the CD30 ectodomain (sCD30), causing a gradual depletion of SGN-35 binding sites on EVs and creating a soluble competitor of the ADC therapy. In a 3D semi-solid tumor microenvironment model, the EVs were retained in the matrix whereas sCD30 penetrated readily into the surrounding culture medium. This resulted in a lowered ratio of EV-associated CD30 (CD30EV) to sCD30 in the surrounding medium in comparison to non-embedded cultures. A low percentage of CD30EV was also detected in the plasma of cHL patients, supporting the clinical relevance of the model. The adherence of CD30EV but not sCD30 to CD30–/CD30L+ mast cells and eosinophils allowed the indirect binding of SGN-35. Moreover, SGN-35 damaged CD30-negative cells, provided they were loaded with CD30+ EVs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.